Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q2 2013 · 10-Q
Revenue$785.61K$785.61K+80.2% vs Q2 2012 Net Income-$10.85M-$10.85MN/M vs Q2 2012 EPS Diluted-$0.24-$0.24N/M vs Q2 2012 Operating Income-$5,672,058N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,448,147N/M Margins · derivedOperating margin-722.0%+834.6 pt vs Q2 2012
Net margin-1381.4%−433.6 pt vs Q2 2012
ended Jun 30, 2013 · filed Aug 9, 2013 · 40 d after period end